The predictive value of IL-6, when using sunitinib as a first line treatment for metastatic RCC patients, has been evaluated; however, these studies enrolled few patients, only those with clear cell types or with poor IMDC risk [30,31]. This evidence concerns the gene IL6 and renal cell carcinoma.